The purpose of this study was to compare two positron emission tomography (PET) tracers that were developed to follow serotonin (5HT) synthesis by performing sequential PET scanning of the same rhesus monkey (n = 4) on the same day. a-[ 11 C]Methyl-L-tryptophan ([ 11 C]AMT) and 5-Hydroxy-L-[b-11 C]tryptophan ([ 11 C]HTP) are substrates in the first and second enzymatic steps, respectively, in the biosynthesis of 5HT. Regional net accumulation rate constants were derived from kinetic (two-tissue compartment model with irreversible tracer trapping) and graphic (Patlak) analyses, using the arterial plasma concentrations as input. The kinetic data analysis showed that the rate constant for the transfer of [ 11 C]HTP into the brain (K 1 ) was higher than that for [ 11 C]AMT in the striatum and thalamus but was similar in other brain regions. The rate constant for tracer trapping (k 3 ) was also higher for [ 11 C]HTP than for [ 11 C]AMT in the striatum (0.04660.024 versus 0.01960.006 min À1 ) and thalamus (0.03960.013 versus 0.01660.007 min À1 ). In agreement with previously reported regional HTP accumulation rates, the net accumulation rate constant (K acc ) for [ 11 C]HTP was also higher in these regions than in other brain regions; this is in contrast to the uniform distribution of [ 11 C]AMT K acc values. This suggests that the regional net accumulation rates obtained with these two PET tracers will be of different magnitude, which might be related to the activity of each targeted enzyme.
Introduction
Early efforts to determine tissue serotonin (5HT) synthesis rates in small mammals typically involved pharmacological manipulation of the 5HT system followed by the sampling of brain tissue (Brown et al, 1979; Goldman-Rakic and Brown, 1981; Karoum et al, 1984; Shannak and Hornykiewicz, 1980; Vriend et al, 1993) . The tissue samples were then analysed for determination of the precursors tryptophan and 5-Hydroxytryptophan (HTP), 5HT itself, and the main metabolite 5-Hydroxyindole acetic acid (HIAA). The radiolabelled compounds a-[ 11 C]Methyl-L-tryptophan ([ 11 C]AMT) (Chandana et al, 2005; Chugani et al, 1998; Fedi et al, 2003; Juhasz et al, 2003; Kagawa et al, 2005; Muzik et al, 1997; Natsume et al, 2003; Nishikawa et al, 2005) and 5-Hydroxy-L-[b-11 C]tryptophan ([ 11 C]HTP) (Agren and Reibring, 1994; Agren et al, 1993; Eriksson et al, 2006; Hagberg et al, 2002; Reibring et al, 1992) have been used in positron emission tomography (PET) in humans for probing the first and second enzymatic steps, respectively, in the biosynthesis of 5HT.
[ 11 C]AMT is a [ 11 C]-methyl analogue of the essential amino acid tryptophan, which is a substrate for tryptophan hydroxylase, the first enzyme in the two-step synthesis of 5HT. Partial conversion of [ 11 C]AMT to a-Methylserotonin (AM-5HT) in the brain has been showed in animals (Diksic et al, 1990; Gharib et al, 1999; Shoaf et al, 2000) in serotonergic neurons and nerve terminals (Cohen et al, 1995) . However, there seems to be a time delay between uptake and conversion of the tracer into AM-5HT (Gharib et al, 1999; Shoaf et al, 2000) . Further, under pathologic conditions, [ 11 C]AMT can occasionally be metabolised by means of the kynurenine pathway and the measurements may thus reflect both pathways (Chugani and Muzik, 2000) .
Apart from the radiolabel, [ 11 C]HTP is identical to the endogenous compound that will undergo conversion to 5HT by aromatic L-amino acid decarboxylase (AADC), the second enzyme in the biosynthesis, and then further catabolism by monoamine oxidase A to HIAA. The timedependent accumulation of radioactivity in the basal ganglia of rats in [ 11 C]HTP/PET is mainly a consequence of the trapping of decarboxylated products (Lindner et al, 1997) , thus providing an in vivo index of the activity of the decarboxylating enzyme AADC. In a previous study, analysis of rat brain homogenates revealed that most of the radioactivity (approximately 75%) was associated with [ 11 C]HIAA 40 mins after intravenous [ 11 C]HTP injection (Lindner et al, 1997) . The decarboxylating enzyme AADC is ubiquitous; the enzyme is expressed in all monoaminergic cells (serotonergic, noradrenergic, and dopaminergic). Hence, it may be possible to follow AADC activity in all of these neuronal cell types using [ 11 C]HTP.
The endogenous concentrations of tryptophan and HTP in the brain are about equal to (Fernstrom and Wurtman, 1971; Young and Gauthier, 1981) , or much less than (Zhu and Juorio, 1995) , the half-saturation concentrations for either of the targeted enzymes (tryptophan hydroxylase and AADC). It has been suggested that measurement of either of these enzymatic steps could provide a value that is proportional to 5HT synthesis (Hagberg et al, 2002) . In previous [ 11 C]AMT/PET and [ 11 C]HTP/PET studies, the net accumulation rate constant for tracer trapping was stable within an individual and the rank order was consistent with the rank order of regional concentrations of 5HT in the human brain (Chugani et al, 1998; Hagberg et al, 2002) . Further, the net accumulation rate constants for tracer trapping obtained in separate [ 11 C]AMT/PET and [ 11 C]HTP/PET studies in humans were found to be correlated (Hagberg et al, 2002; Leyton et al, 2005) . The purpose of this study was to directly compare [ 11 C]AMT and [ 11 C]HTP as PET ligands for 5HT synthesis capacity in rhesus monkeys.
Materials and methods

Animals
Four female rhesus monkeys (Macaca mulatta) (Primate Research Laboratory, Uppsala University), aged 15 to 20 years and weighing 6 to 13 kg, were allowed only water from the evening before the PET study. The Animal Ethics Committee of Uppsala University approved the protocol (C 117/04).
Radiochemistry
[ 11 C]AMT and [ 11 C]HTP were synthesised as described previously (Bjurling et al, 1989; Chakraborty et al, 1996) . Radiochemical purity was greater than 95%. The mean specific radioactivity levels of [ 11 C]AMT and [ 11 C]HTP at the time of injection were 17710 and 1576 GBq/mmol, respectively. The average injected [ 11 C]AMT radioactivity dose was 2927125 MBq, corresponding to a total amount of injected unlabelled AMT of 2078 nmol. The average injected [ 11 C]HTP dose was 2847157 MBq and contained 1973 nmol of unlabelled HTP.
Positron Emission Tomography System
The studies were performed using the Hamamatsu SHR-7700 (Hamamatsu Photonics KK, Hamamatsu, Japan). The 16 detector rings of this instrument provide a 114 mm axial FOV and 31 two-dimensional image planes for every 3.6 mm distance. The transaxial resolution is 3 mm in 2D mode (Watanabe et al, 1997) . Transmission scans with rotating 68 Ge sources were used to correct the emission scans for the attenuation of 511 keV photons through the tissue and head supports. Images were reconstructed using a 4 mm Hanning filter after correction for attenuation and scattered radiation.
Positron Emission Tomography Studies
After induction of anaesthesia with 100 mg intramuscular ketamine (Ketaminol, Vetpharma, Zurich, Switzerland), the animals were transported to the investigation site at Uppsala Imanet. A venous catheter was inserted in both hind legs of each monkey, one for administration of the anaesthetic agent propofol (8 to 12 mg/kg/h, Propofol-Lipuro, B/Brown) and one for administration of the radioactive tracer. After tracheal intubation, muscle relaxation was achieved with 5 mg/kg/h intravenous atracurium (Tracrium, GlaxoSmithKline). Ventilation was supported with 30% oxygen in air. Heating pads were used to maintain body temperature at 371C to 381C. A femoral artery catheter was inserted for blood sampling. PET scans with [ 11 C]AMT and [ 11 C]HTP were performed sequentially on the same day within the same monkey at least 2 h apart. The first PET scan was performed at least 2 h after ketamine administration. Radioactivity in the brain was measured in a series of sequential frames of increasing duration (from 15 secs to 3 mins) for a total of 60 mins after injection of the tracer. An automatic blood sampling system was used to measure radioactivity in arterial whole blood for the first 2 to 3 mins after radiotracer administration. Thereafter, 4 to 7 manual arterial blood samples were drawn at 5, 10, 15, 20, 30, 40 , and 60 mins. The radioactivity concentration in blood and plasma was measured in a g-counter (Well-type, NaI(Tl) scintillation counter), which was cross-calibrated against the PET scanner. Plasma-to-blood radioactivity concentration ratios determined from the manual samples were used to transform the blood radioactivity-time curve measured by the automatic sampling system into the full plasma radioactivity-time curve. Because plasma radioactivity after [ 11 C]AMT is mainly associated with unchanged tracer (Gharib et al, 1999) , [ 11 C]AMT plasma/blood samples were directly counted on the g-counter. For [ 11 C]AMT, the generated total plasma radioactivity-time curve was then used in the model to represent the plasma input function (C inp ). For [ 11 C]HTP, the remaining volume of each manual plasma sample collected at 5, 20, 40, and 60 mins was used to determine the fraction of unchanged radioligand and its radiolabelled metabolites in plasma over time. The metabolite-corrected plasma radioactivity-time curve generated from the plasma curve and the data describing the unchanged fraction of [ 11 C]HTP was then used in the model to represent the plasma input function (C inp ).
Determination of [ 11 C]HTP Metabolism in Plasma
The composition of the [ 11 C]-derived radioactivity was analysed with high-performance liquid chromatography (HPLC) as described previously (Lindner et al, 1995) , with minor modifications. Blood samples were centrifuged at 4000 r.p.m. for 2 mins at 41C to obtain plasma (Beckman Allegra X-22R Centrifuge, Palo Alto, USA). Proteins were then precipitated with 1 mL acetonitrile in 1 mL plasma. After centrifugation for 1 min at 14000 r.p.m. (Eppendorf 5415R centrifuge, Eppendorf AG, Hamburg, Germany), the supernatant was filtered through a nylon membrane (0.2 mm, Corning Inc., Corning, NY, USA). The extent of sample recovery was determined by measuring the radioactivity in the plasma, the filters and the pellet. HPLC analysis was performed using a binary pump system (Gilson, Middleton, USA) with an automated solid phase extraction controller (ASPEC Gilson) connected to a dilutor (Gilson). Before injection of the sample (1.5 mL) into the HPLC column, 10 mL of unlabelled reference compounds (1 mg/mL of HTP, 5HT and HIAA) was added to the supernatant. Separation was performed on a C-18 column (Genesis, 7 mm, 250 Â 10 mm 2 , Jones Chromatography). The mobile phase comprised acetonitrile and 50 mmol/L ammonium formiate (pH 3.5). The concentration of acetonitrile was varied during the process to provide graded concentration ratios with ammonium formiate: 0 to 9 mins, concentration ratio 5:95; 9 to 11 mins, ratio 70:30; 11 to 12 mins, isocratic; and then reconditioned with the 5:95 mobile mixture for at least 2 mins. A UV detector (Gilson) was used to detect the unlabelled reference substances at 275 nm. The outlet from the detector was connected to a switching valve on the arm of the ASPEC to enable automatic fraction collection. Seven fractions were collected and their respective radioactivity levels were measured in the gcounter. A radio detector (Radiomatic 505TR, Packard, USA) was coupled online to the column to verify the fraction times and the radioactivity measurement.
Regions of Interest
Time frames were added to obtain a summation image, on which the regions of interest (ROIs; the frontal, occipital, parietal, and temporal cortices, the cerebellum, the striatum, the thalamus and the whole brain) were outlined, using a rhesus monkey brain atlas for guidance (Paxinos et al, 2000) . Where appropriate, the same brain tissue region was delineated in two adjacent sections for both hemispheres, and data from the same region were pooled to obtain the average radioactivity concentration in that region. The total regional radioactivity concentration for each time frame corrected for radioactive decay (C s, tiss ) was plotted versus time for use in tracer modelling.
Data Analysis
Regional net accumulation rate constants were derived with kinetic and graphic analysis of the regional radioactivity-time curves using the plasma input function. The contribution of blood radioactivity to the measured regional radioactivity was removed, assuming a 3% to 5% blood volume in the ROI. In this study, the blood volume was fixed at 5% for the cerebellum and occipital cortex, 4% for the thalamus and temporal, parietal, and frontal cortices, and 3% for the striatum and whole brain. Values were based on estimates from previous quantitative blood volume measurements using labelled carbon monoxide performed at Uppsala Imanet, and literature values (Eichling et al, 1975; Hagberg et al, 2002; Muzik et al, 1997) . The use of fixed blood volumes reduces the number of free parameters (from 4 to 3), which allowed a more precise estimation of the individual rate constants. Kinetic and graphic parameters were derived using software developed in-house implemented in MATLAB 6.5 (The Math Works Inc., Natick, MA, USA).
Kinetic analysis:
The compartment model used for describing the kinetics of both [ 11 C]AMT and [ 11 C]HTP in humans is a two-tissue compartment model (2TCM, Figure 1 ), which assumes irreversible radioactivity trapping in the second tissue compartment (Chugani et al, 1998; Hagberg et al, 2002) . The rate constants K 1 (mL plasma/mL tissue/min) and k 2 (min À1 ) describe the influx and efflux, respectively, for radioligand transport between vascular space and the cell cytoplasm (transport across the blood-brain barrier, the interstitial space, and the cell membrane). Once [ 11 C]AMT is present in the cell cytoplasm it is converted to [ 11 C]AM-5HT by means of twostep enzymatic process (via [ 11 C]AM-HTP), which is characterised by the rate constant k 3 (min À1 ). For [ 11 C]HTP, the conversion to [ 11 C]5HT is a 1-step enzymatic process. The rate constant k 3 (min À1 ) describes the trapping of [ 11 C]HTP and its decarboxylated products (i.e. [ 11 C]5HT and the subsequently formed metabolite [ 11 C]HIAA). The operational equation for the 2TCM is
where V b is the fractional blood volume for correction of the vascular component, C inp is the plasma input function, y(t) is the Heaviside step function, and C b is the wholeblood radioactivity-time curve. Kinetic parameters were derived by nonlinear regression using a Marquardt-Levenberg least-square minimisation procedure implemented in MATLAB (Levenberg, 1944; Marquardt, 1963) . The net accumulation rate constant, K acc (mL plasma/mL tissue/min), was calculated from the estimated individual rate constants as the ratio
Graphic Analysis: For a tracer with irreversible kinetics, Patlak et al (Patlak et al, 1983) showed that, in a plot of C s,tiss /C inp versus R t 0 C inp =C inp , the data will eventually (t > t*) approach a straight line with a slope (K pPat ) equal to the net accumulation rate constant. When the 2TCM model is valid, the slope will theoretically be equal to K acc (equation 2). Thus, linear regression of the transformed data (straight line fitted to the data above t = t*) yields this macroparameter. The linear fits in this study were performed between 30 and 60 mins to correspond with previous analyses of human (Hagberg et al, 2002; Muzik et al, 1997) and rhesus monkey data (Lundquist et al, 2006; Shoaf et al, 1998; Shoaf et al, 2000) .
Statistical Analysis
A two-way ANOVA for repeated measurements on both factors (ROI and tracer) was used for comparison of the parameters. The null hypothesis was rejected at a 5% significance level (Bonferroni post-test).
Results
Plasma Radioactivity
The time course of the radioactivity concentration in arterial plasma (input function) is shown in Figure  2A . The plasma-to-blood ratio was 0.8 to 0.9 at all measured time points for both tracers. The fraction of unmetabolised [ 11 C]HTP in plasma decreased as the study progressed to 50% at 60 mins ( Figure 2B ). The major peripheral metabolite was [ 11 C]HIAA; at the end of the scan, 39% of the total plasma radioactivity was associated with this metabolite.
Brain Tissue Radioactivity
Positron emission tomography images for the two radiotracers in one rhesus monkey are shown in Figure 3 . The whole brain uptake of [ 11 C]AMT and [ 11 C]HTP was low, with only a small percentage of the injected dose present in the brain at peak values. Regional brain tissue radioactivity-time curves obtained after intravenous injection of [ 11 C]AMT and [ 11 C]HTP are shown in Figure 4 . For [ 11 C]AMT, there were no substantial differences in radioactivity concentrations among the outlined brain regions. The [ 11 C]AMT radioactivity peaked later than the [ 11 C]HTP-derived radioactivity. For [ 11 C]HTP, the highest tissue radioactivity concentration was observed in the striatum. There were no substantial differences in radioactivity levels among the outlined extrastriatal brain regions for [ 11 C]HTP. The striatal [ 11 C]HTP-derived radioactivity concentration was almost the same as for [ 11 C]AMT, but was higher for [ 11 C]AMT in all other brain regions. This was expected, since the unchanged fraction of [ 11 C]HTP in plasma available for brain uptake is lower than that of [ 11 C]AMT after the same dose of radioactivity (Figure 2A ).
Kinetic Analysis
Results obtained using the 2TCM are presented in Table 1 . Convergence was reached for 58 of 64 fits (four [ 11 C]AMT and two [ 11 C]HTP fits did not converge). Five of the six fits that did not converge came from the same PET experiment. The radioactivity signal was low, which probably contributed to the poor modelling of the data. The estimates of the individual rate constants and the net accumulation rate constant, K acc , were highly variable for both tracers, as assessed by the relative standard deviation (100% s.d./mean). K 1 was higher for [ 11 C]HTP in the striatum (0.02770.009 versus 0.02270.008 mL/ mL min) and thalamus (0.02570.011 versus 0.0207 0.008 mL/mL min) than for [ 11 C]AMT (P < 0.05). In other brain regions, similar K 1 values were observed for the two tracers. Compared with [ 11 C]AMT, k 3 was higher for [ 11 C]HTP in the striatum (0.04670.024 versus 0.01970.006 min À1 ) and thalamus (0.0397 0.013 versus 0.01670.007 min À1 ) (P < 0.05). In the same brain regions, K acc was higher for [ 11 C]HTP than the corresponding [ 11 C]AMT scan value within the same monkey (P < 0.05).
Graphic Analysis
Examples of Patlak analysis of [ 11 C]AMT and [ 11 C]HTP data for one monkey are shown in Figure 5 . The data indicate a linear relationship between the apparent partition coefficient (tissue: Figure 3 PET images for the radiotracers [ 11 C]AMT (A) and [ 11 C]HTP (B) in one rhesus monkey. The images were derived from radioactivity collected between 30 and 60 mins after tracer injection. Intensities were normalised to the injected radioactivity dose. The transaxial plane is at the level of the striatum. plasma ratio) for the brain regions and the normalised plasma concentration-time integral for both tracers from 30 to 60 mins of the experiment. The plots show that, with the same magnitude of the plasma input function, the net uptake over time is higher for [ 11 C]HTP than for [ 11 C]AMT.
The result using graphic parameter estimation is shown in Table 2 . In general, the Patlak fitted values (K pPat ) agreed well with K acc calculated from the individual rate constants. However, for [ 11 C]AMT, the striatal K pPat value was lower than the corresponding K acc value. In the occipital cortex, K acc for [ 11 C]HTP was higher than K pPat and showed greater variability. However, the two fits that did not converge for [ 11 C]HTP in the kinetic analysis were from this particular brain region and the mean K acc was therefore only based on estimates from two monkeys. The Patlak slope was higher for [ 11 C]HTP in the striatum (0.00970.003 versus 0.0047 0.002 mL/mL min) and thalamus (0.00870.003 versus 0.00570.002 mL/mL min) than the corresponding [ 11 C]AMT scan value in the same monkey (P < 0.05).
Discussion
In this paper, a direct comparison of two tracers used in PET for probing the first and second enzymatic steps in the biosynthesis of 5HT is presented.
The only pathway available for blood-borne amino acid entry to the brain is carrier-mediated transport through the blood-brain barrier (Pardridge, 1998) . For large neutral amino acids (LNAA: tryptophan, tyrosine, phenylalanine, valine, isoleucine, and leucine), the barrier across cell membranes, including the blood-brain barrier, comprises the sodium-independent L system (Pardridge and Oldendorf, 1977) . The entry of plasma HTP into the brain is competitive with L-valine and thus presumably with other large neutral amino acids (Amer et al, 2004) . Estimates of the Michaelis-Menten constants for blood-brain barrier transport of labelled AMT have been shown to agree reasonably with those previously measured for tryptophan (Diksic et al, 1991) . It has also been shown that there is a highly significant correlation in the rat brain between the permeability surface area products for labelled AMT and those for tryptophan (Diksic et al, 2000) . In the present study, the total radioactivity concentration among brain regions (except for the striatum) was 30% to 50% higher for [ 11 C]AMT than for [ 11 C]HTP after the same injected amount of radioactivity to the same monkey. However, as [ 11 C]HTP is subject to decarboxylation by AADC in the periphery, the fraction of unmetabolised [ 11 C]HTP in plasma available for brain uptake would have decreased as the study progressed, which probably influenced the brain concentration of [ 11 C]HTP. The results of the kinetic data analysis showed that the rate constant for the transfer of [ 11 C]HTP into the brain (K 1 ) was similar to or even higher than for [ 11 C]AMT (striatum and thalamus). The results in Figure 5 also show that the ratio C s,tiss /C inp over time is higher for [ 11 C]HTP than for [ 11 C]AMT, which also reflects the higher influx and radioactivity trapping for the former tracer. Shoaf et al (1998 Shoaf et al ( , 2000 and Gharib et al (1999) argued that [ 11 C]AMT cannot be used to measure 5HT synthesis since only a fraction of the AMT taken up into the tissue is converted to AM-5HT. In monkeys, approximately 2% to 4% of the total radioactivity in the dorsal raphe nucleus was [ 14 C]AM-5HT after 90 mins (Shoaf et al, 2000) . These research groups both concluded that [ 11 C]AMT is primarily a measure of brain uptake of tryptophan and cannot be related to 5HT synthesis. A further concern was that tryptophan is also a substrate for protein synthesis. However, in subsequent auto-radiographic studies, Diksic and co-workers showed that pharmacological inhibition of tryptophan hydroxylase with p-chlorophenylalanine (Tohyama et al, 2002) or AGN-2979 (Hasegawa et al, 2005) decreased the unidirectional trapping of [ 14 C]AMT. A protein synthesis inhibitor (cycloheximide) was also examined but this had no effect on [ 14 C]AMT trapping in brain tissue (Tohyama et al, 2002) . These findings suggest that brain trapping of [ 14 C]AMT relates to brain 5HT synthesis but not to brain protein synthesis.
In the present study, the rank order of the net accumulation rate constant measured with [ 11 C]HTP/PET was in agreement with previous post-mortem regional HTP accumulation rates in the rhesus monkey brain (Brown et al, 1979) , namely: highest in the striatum, intermediate in the thalamus and lowest in cortical areas. While there were no substantial differences in K acc for [ 11 C]AMT among the outlined brain regions, this was consistent with the results of an earlier study in rhesus monkeys (Shoaf et al, 2000) . Thus, in contrast to two previous reports (Hagberg et al, 2002; Leyton et al, 2005) , the net accumulation rate constants of [ 11 C]HTP and [ 11 C]AMT were not well correlated. Previously, it was observed that the rank order of regional [ 11 C]AMT K-complex (or K pPat ) values in humans matched that of the 5HT content, but the contrast (i.e. magnitude of difference) between brain regions was much lower for Kcomplex than for 5HT content (Chugani and Muzik, 2000) . The authors interpreted the difference to mean that there is a large unmetabolised pool of [ 11 C]AMT trapped in brain tissue. This might also explain the discrepancy between [ 11 C]AMT and [ 11 C]HTP in the regional contrast of the net accumulation rate constant seen in our study.
In this study, the compartmental analysis results for the net accumulation rate constant were compared with those obtained using the graphic method of Patlak. In view of the limited PET scanning time, it was critical for the linearity to appear early enough for accurate parameter estimation from the Patlak slope. In some regions, the Patlak plot linearity appeared later for [ 11 C]AMT than for [ 11 C]HTP. However, the graphically obtained estimates of the net accumulation rate constant for [ 11 C]AMT were quite similar to or somewhat lower (striatum) than the corresponding values of the kinetic analysis. In a previous study using labelled AMT in rhesus monkeys, the final slope of the Patlak curve at 180 mins was small and not statistically different from zero (Shoaf et al, 2000) . This limiting, almost horizontal Patlak distribution indicates that the tracer should be treated as reversible during extended measuring times (180 mins). A possible mechanism for the reversible kinetics can be derived from the observation that the rate constant for the [ 11 C]HTP transfer out of the brain (k 2 ) is substantial. If [ 11 C]AMT follows the endogenous 5HT synthesis pathway, it will first be transformed into [ 11 C]AM-HTP before it is converted into [ 11 C]AM-5HT. It is, thus, likely that [ 11 C]AM-HTP may leave the tissue via the same transport process as [ 11 C]HTP. Such a mechanism might also be a factor behind the lower regional contrast observed for [ 11 C]AMT than for [ 11 C]HTP.
It seems reasonable that the measures obtained with these PET tracers should be different as the tracers target different enzymes that differ in their enzyme activity in the brain (Ichiyama et al, 1968) . In recent autoradiographic studies, pharmacological inhibition of tryptophan hydroxylase with p-chlorophenylalanine or AGN-2979 decreased the unidirectional trapping of [ 14 C]AMT (Hasegawa et al, 2005; Tohyama et al, 2002) . In rats (Lindner et al, 1997) and rhesus monkeys (Lundquist et al, 2006) , pharmacological inhibition of AADC by NSD1015 decreased the trapping rate constant of [ 11 C]HTP. This suggests that K acc of [ 11 C]AMT gives a reasonable estimate of the activity of tryptophan hydroxylase while K acc of [ 11 C]HTP is providing an in vivo index of the activity of the decarboxylating enzyme AADC. In the present study, the extent and distribution of the irreversible binding of [ 11 C]AMT was different from those for [ 11 C]HTP. This also suggests that the two probe compounds provide estimates related to the enzyme activity of the different targeted steps. However, more in vivo validation studies involving drugs inhibiting the enzymes involved in 5HT formation need to be investigated if more general conclusions are to be drawn about the suitability of these tracers for estimating 5HT synthesis. It would be interesting to study the effect of a tryptophan hydroxylase inhibitor on [ 11 C]HTP accumulation in vivo as well as possible reasons for the high tracer accumulation seen in striatal regions. Given the high level of dopaminergic innervation in the striatum, it seems likely that the discrepancy between the tracer accumulation in the striatum and that in other areas is due to the presence of AADC in dopaminergic terminals. Further, the combination of the two tracers in this study might provide a deeper insight into the pathways of tryptophan in the brain tissue.
In certain pathologic states, the accumulation of [ 11 C]AMT in tissue may represent metabolites of the kynurenine pathway rather than of 5HT synthesis. Thus, the combination [ 11 C]HTP/[ 11 C]AMT might provide a measure to distinguish between these two metabolic pathways as the two tracers probe different enzymatic steps. Further, in light of the large unmetabolised pool of [ 11 C]AMT in contrast to the rapidly metabolised [ 11 C]HTP, a combination might also be useful when investigating the regulation of amino acid transport across cell membranes and the distribution into different tissue compartments.
In conclusion, the PET tracers [ 11 C]AMT and [ 11 C]HTP might be useful for in vivo monitoring of 5HT synthesis capacity. Additional pharmacological in vivo studies using enzyme-inhibiting drugs in 5HT formation need to be performed, if more general conclusions are to be drawn about their respective predictive capacity of 5HT synthesis. The validated methodologies could be used to address a wide range of issues relevant to the regulation of enzyme activity and mechanisms of psychiatric and neurologic disorders.
